JPRN-jRCT2080220881未知1 期
A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metastatic Unresectable Gastric Cancer
适应症
试验速览
- 阶段
- 1 期
- 发起方
- AstraZeneca
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histological or cytological confirmation of gastric adenocarcinoma (including the gastric cardia andesophagogastric jungtion).
- •- Having locally adcanced or metastatic gatric cancer for which they must have received no prior systemic therapy for locally advanced disease. Previous gastrectomy, neoadjuvant and adjuvant therapy received > 6 months ago are acceptable.
- •-Having a mild symptom in ordinal daily lives including walking and simple labour or works in the sitting position.
排除标准
- •- A history of poorly controlled hypertension or resting BP > 150/100 mmHg in the presence or absence of a stable regimen of anti-hypertensive therapy or patients who are requiring maximal doses of calcium channel blockers to stabilize BP.
- •- Significant Haemorrhage (> 30 ml bleeding/episode in previous 3 months) or haemoptysis (> 5 ml fresh blood in previous 4 weeks).
- •- Arterial thromboembolic event (including ischemic attack) in the previous 12 months.
研究者
相似试验
招募中
不适用
A Phase I, Open-label, Non-randomised Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of a Single Oral Dose of AZD9291 in Patients with EGFRm Positive NSCLC Whose Disease has Progressed on an EGFR TKIProgressive Non Small Cel Lung Cancer with positive epidermal growth factor receptor10038666NL-OMON45155Astra Zeneca5
已完成
1 期
A study to characterize the impact of dietary modification on inavolisib associated hyperglycaemia and to assess the CYP3A4 induction potential of inavolisib using midazolam as a probe substrate in participants with incurable metastatic solid tumours previously treated with multiple (=2) lines of therapyMetastatic solid tumoursCancerISRCTN12839469F. Hoffmann-La Roche Ltd3
进行中（未招募）
1 期
Study that tested S64315 plus different standard treatments in patients with breast cancerEUCTR2019-000998-23-ESInstitut de Recherches Internationales Servier
已完成
1 期
A Phase I, Randomised, Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Doses of ATL1102 Alone and in Combination with G-CSF in Healthy VolunteersStem cell mobilisationBlood - Haematological diseasesACTRN12614000200684Antisense Therapeutics10
已完成
1 期
An Open Labeled, Noncomparative, Phase I Study to Evaluate the Safety and Tolerability of a Fully Liquid Pentavalent DTwP-Hib-IPV Vaccine (EasyfourpolTM) of Panacea Biotec Ltd. Administered in Healthy Children 15- 18 Months of age.CTRI/2010/091/001261Panacea Biotec Ltd24